Health
Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC – OncLive
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation…
Because no standard approaches exist for patients with EGFR-mutated nonsmall cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD.
This is a very hot topic now. There are some potential rare, resistant mechanisms that could be a secondary actionable mutation such as MET amplification where you can potentially…
-
Noosa News23 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
Noosa News12 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News22 hours agoWoman loses arm in lion attack at Darling Downs Zoo in Queensland
-
General19 hours agoJordan Thompson retires from Wimbledon round-of-16 match with American Taylor Fritz